When RNF180 and SFRP2 methylation were combined, the OR (95% CI) for cancer prediction [OR, 5.57 (2.13–14.57); P=0.0002] was superior to that for RNF180 methylation alone [OR, 4.40 (1.82–10.65); P=0.0007]; however, the specificity (47.62%) for cancer prediction was markedly lower than that of RNF180 methylation alone (76.19%). The gene discussed is SFRP2; the disease is cancer.